<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03872427</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2019-01365</org_study_id>
    <secondary_id>NCI-2019-01365</secondary_id>
    <secondary_id>NCI10220</secondary_id>
    <secondary_id>10220</secondary_id>
    <secondary_id>10220</secondary_id>
    <secondary_id>UM1CA186688</secondary_id>
    <nct_id>NCT03872427</nct_id>
  </id_info>
  <brief_title>Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study</brief_title>
  <official_title>A Phase II Basket Trial of Glutaminase Inhibitor (BeGIN) CB-839 HCl in Patients With NF1 Aberrations, NF1 Mutant Malignant Peripheral Nerve Sheath Tumors (MPNST), KEAP1/NRF2 and LKB1 Aberrant Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well glutaminase inhibitor telaglenastat hydrochloride&#xD;
      (CB-839 HCl) works in treating patients with specific genetic mutations and solid tumors or&#xD;
      malignant peripheral nerve sheath tumors that have spread to other places in the body&#xD;
      (metastatic) or cannot be removed by surgery (unresectable). Glutaminase converts an amino&#xD;
      acid (building block of proteins) called glutamine to glutamate, which can support several&#xD;
      cellular pathways. Telaglenastat hydrochloride works by blocking glutamine activity needed&#xD;
      for the growth of cells. When this activity is blocked, the growth of cancer cells may stop&#xD;
      and the cancer cells may then die. Cancer is caused by changes (mutations) to genes that&#xD;
      control the way cells function and uncontrolled cell growth may result in tumor formation.&#xD;
      Specific genetic mutations studied in this clinical trial are NF1 mutation for malignant&#xD;
      peripheral nerve sheath tumors, and NF1, KEAP1/NRF2, or STK11/LKB1 mutation for other solid&#xD;
      tumors. Telaglenastat hydrochloride may stop the growth of tumor cells by blocking some of&#xD;
      the enzymes needed for cell growth.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To assess the best overall response rate (BORR) achieved by 6 months of telaglenastat&#xD;
      (CB-839) hydrochloride (HCl) treatment in specific pathway aberrant tumors (MPNST, NF1,&#xD;
      KEAP1/NRF2 &amp; STK11/ LKB1).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety, progression-free survival (PFS), time to progression (TTP) and&#xD;
      overall survival (OS).&#xD;
&#xD;
      II. To determine the overall response rate (ORR) (highest objective response achieved between&#xD;
      start of therapy and progression), time to response (TTR) and clinical benefit rate (CBR) of&#xD;
      telaglenastat (CB-839)HCl.&#xD;
&#xD;
      III. To assess pharmacodynamic changes and adaptive responses and correlate with response to&#xD;
      treatment as well as disease progression (correlative objective).&#xD;
&#xD;
      EXPLORATORY OBJECTIVES:&#xD;
&#xD;
      I. Correlate fludeoxyglucose F-18 (18-F FDG) positron emission tomography (PET)/computed&#xD;
      tomography (CT) pre-therapy and 8-weeks post-therapy response to telaglenastat (CB-839) HCl&#xD;
      therapy.&#xD;
&#xD;
      II. Evaluate changes in level of circulating tumor deoxyribonucleic acid (DNA) at baseline,&#xD;
      one month on-treatment and time of progression to treatment response.&#xD;
&#xD;
      III. Quantify the peripheral blood concentrations of the metabolites: aspartate, glutamate,&#xD;
      glutamine and arginine and correlate with response.&#xD;
&#xD;
      IV. Evaluate the pharmacodynamic (PD) effect of telaglenastat (CB-839) HCl on systemic levels&#xD;
      of the tricarboxylic acid (TCA) cycle metabolites in peripheral blood (baseline and one&#xD;
      month) as part of the protocol.&#xD;
&#xD;
      V. Evaluate tumor by reverse phase protein array and ribonucleic acid (RNA) sequencing (seq)&#xD;
      to evaluate changes from pre-treatment, during treatment and post treatment specimens.&#xD;
&#xD;
      VI. Perform patient-derived tumor xenograft (PDX) modelling-co-clinical trials to understand&#xD;
      response/resistance mechanisms and also evaluate combination therapies for future&#xD;
      development.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive telaglenastat hydrochloride orally (PO) twice daily (BID) on days 1-28.&#xD;
      Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up every 3 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 26, 2019</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Best overall response rate</measure>
    <time_frame>Up to 6 months from treatment start date</time_frame>
    <description>Will be based on Response Evaluation Criteria in Solid Tumors version 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years from treatment start date</time_frame>
    <description>Will be assessed by Common Terminology Criteria for Adverse Events version 5.0. Will tabulate toxicity by cohort, type, severity and attribution.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time to progression or death whichever comes first, assessed up to 2 years from treatment start date</time_frame>
    <description>Will estimate using the Kaplan-Meier method with time zero set to cycle 1, day 1 (C1D1). Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Time to progression starting at C1D1, assessed up to 2 years from treatment start date</time_frame>
    <description>Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Time to death from any cause, assessed up to 2 years from treatment start date</time_frame>
    <description>Will estimate using the Kaplan-Meier method with time zero set to C1D1. Will estimate the medians and select probabilities along with 95% confidence intervals. If more than a handful of patients die without progression, will use Aalen-Johansen estimates to adjust for the competing risk of death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>From start of treatment until disease progression/recurrence, assessed up to 2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate</measure>
    <time_frame>Up to 2 years from treatment start date</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Pharmacodynamic (PD) tumor oncometabolite levels of glutamine</measure>
    <time_frame>Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose</time_frame>
    <description>Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD tumor oncometabolite levels of glutamate</measure>
    <time_frame>Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose</time_frame>
    <description>Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.</description>
  </other_outcome>
  <other_outcome>
    <measure>PD tumor oncometabolite levels of aspartate</measure>
    <time_frame>Baseline up to between 0-8 hours post-glutaminase inhibitor CB-839 hydrochloride dose</time_frame>
    <description>Will assess PD changes before and after treatment using the Wilcoxon signed rank test. Will correlate these changes with response to treatment using Wilcoxon rank sum test. Will also perform a receiver operating characteristic curve analysis.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Advanced Malignant Solid Neoplasm</condition>
  <condition>Metastatic Malignant Solid Neoplasm</condition>
  <condition>NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor</condition>
  <condition>Unresectable Malignant Solid Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment (telaglenastat hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive telaglenastat hydrochloride PO BID on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacodynamic Study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (telaglenastat hydrochloride)</arm_group_label>
    <other_name>PHARMACODYNAMIC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telaglenastat Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (telaglenastat hydrochloride)</arm_group_label>
    <other_name>CB-839 HCl</other_name>
    <other_name>Glutaminase Inhibitor CB-839 Hydrochloride</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have histologically confirmed malignancy that is metastatic or&#xD;
             unresectable&#xD;
&#xD;
          -  Patient must have histopathologic confirmation of advanced solid tumor with NF1&#xD;
             mutation, NF1 mutant MPNST, KEAP1/NRF2 mutant and STK11/LKB1 mutant tumors (molecular&#xD;
             profiling performed in any Clinical Laboratory Improvement Act [CLIA] certified lab&#xD;
             [including tumor and circulating cell-free (cf)DNA], e.g. Caris, FoundationOne,&#xD;
             FoundationAct, Oncomine, Guardant etc.)&#xD;
&#xD;
               -  NOTE: For all cohorts annotation for actionability will be performed by the&#xD;
                  PRECISION ONCOLOGY DECISION SUPPORT (PODS) TEAM SHEIKH KHALIFA BIN ZAYED AL&#xD;
                  NAHYAN INSTITUTE FOR PERSONALIZED CANCER THERAPY (IPCT) THE UNIVERSITY OF TEXAS&#xD;
                  MD ANDERSON CANCER CENTER 6565 MD ANDERSON BLVD, HOUSTON, TX 77030&#xD;
&#xD;
          -  Patient must have no standard therapies available&#xD;
&#xD;
          -  Patient must be aged greater than 18 years old for all cohorts&#xD;
&#xD;
          -  Patients for NF1 mutant MPNST and NF1 mutant non-MPNST cohorts must be &gt;= 40 kg&#xD;
&#xD;
          -  Patient must be at least 4 weeks since any prior surgery or radiotherapy&#xD;
&#xD;
          -  Females of childbearing potential must have a negative serum pregnancy test (=&lt; 14&#xD;
             days) prior to start of trial treatment&#xD;
&#xD;
          -  Response Evaluation Criteria in Solid Tumors (RECIST) measurable disease and&#xD;
             biopsiable targetable lesion&#xD;
&#xD;
          -  Patients must have measurable disease, defined as at least one lesion that can be&#xD;
             accurately measured in at least one dimension (longest diameter to be recorded for&#xD;
             non-nodal lesions and short axis for nodal lesions) as &gt;= 20 mm (&gt;= 2 cm) by chest&#xD;
             x-ray or as &gt;= 10 mm (&gt;= 1 cm) with CT scan, magnetic resonance imaging (MRI), or&#xD;
             calipers by clinical exam&#xD;
&#xD;
          -  Patients with treated brain metastases are eligible if there is no evidence of&#xD;
             progression for at least 4 weeks after central nervous system (CNS)-directed&#xD;
             treatment, as ascertained by clinical examination and brain imaging (MRI or CT) during&#xD;
             the screening period&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral&#xD;
             therapy with undetectable viral load within 6 months are eligible for this trial&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status =&lt; 2 (Karnofsky &gt;= 60%)&#xD;
&#xD;
          -  Leukocytes &gt;= 3,000/mcL&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,000/mcL&#xD;
&#xD;
          -  Platelets &gt;= 100,000/mcL&#xD;
&#xD;
          -  Total bilirubin =&lt; 1.5 x institutional upper limit of normal (ULN) and up to 3 ml/dL&#xD;
             for patients with Gilbert's disease&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase&#xD;
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])&#xD;
             =&lt; 3 x institutional ULN and =&lt; 5 x institutional ULN for patients with liver&#xD;
             metastases&#xD;
&#xD;
          -  Creatinine =&lt; institutional ULN, as age appropriate OR&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &gt;= 30 mL/min/1.73 m^2 for patients with creatinine&#xD;
             levels above institutional normal&#xD;
&#xD;
          -  The effects of telaglenastat (CB-839) HCl on the developing human fetus are unknown.&#xD;
             For this reason and because anti-metabolic agents like telaglenastat (CB-839) HCl are&#xD;
             known to be teratogenic, women of child-bearing potential and men must agree to use&#xD;
             adequate contraception (hormonal or barrier method of birth control; abstinence) prior&#xD;
             to study entry and for the duration of study participation. Should a woman become&#xD;
             pregnant or suspect she is pregnant while she or her partner is participating in this&#xD;
             study, she should inform her treating physician immediately. Men treated or enrolled&#xD;
             on this protocol must also agree to use adequate contraception prior to the study, for&#xD;
             the duration of study participation, and 4 months after completion of telaglenastat&#xD;
             (CB-839) HCl administration&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for&#xD;
             nitrosoureas or mitomycin C) prior to entering the study&#xD;
&#xD;
          -  Patients who have not recovered from adverse events due to prior anti-cancer therapy&#xD;
             (i.e., have residual toxicities &gt; grade 1)&#xD;
&#xD;
          -  Patients who are receiving any other investigational agents&#xD;
&#xD;
          -  History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition to telaglenastat (CB-839) HCl&#xD;
&#xD;
          -  Patients with glioma will be excluded&#xD;
&#xD;
          -  Patients with active or prior history of hepatitis B or C will be excluded&#xD;
&#xD;
          -  Telaglenastat (CB-839) HCl is a weak in vitro inhibitor of CYP2C9. Therefore, patients&#xD;
             receiving any medications or substances that are substrates of CYP2C9 are eligible,&#xD;
             but should use caution with substrates that have a narrow therapeutic index. Because&#xD;
             the lists of these agents are constantly changing, it is important to regularly&#xD;
             consult a frequently-updated medical reference. As part of the enrollment/informed&#xD;
             consent procedures, the patient will be counseled on the risk of interactions with&#xD;
             other agents, and what to do if new medications need to be prescribed or if the&#xD;
             patient is considering a new over-the-counter medicine or herbal product&#xD;
&#xD;
          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant women are excluded from this study because telaglenastat (CB-839) HCl is&#xD;
             anti-metabolic agent with the potential for teratogenic or abortifacient effects.&#xD;
             Because there is an unknown but potential risk for adverse events in nursing infants&#xD;
             secondary to treatment of the mother with telaglenastat (CB-839) HCl, breastfeeding&#xD;
             should be discontinued if the mother is treated with telaglenastat (CB-839) HCl&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Subbiah</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas MD Anderson Cancer Center LAO</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham Cancer Center</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>205-934-0220</phone>
      <email>tmyrick@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Aparna Hegde</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Aventura</name>
      <address>
        <city>Aventura</city>
        <state>Florida</state>
        <zip>33180</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>954-461-2180</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Coral Gables</name>
      <address>
        <city>Coral Gables</city>
        <state>Florida</state>
        <zip>33146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Deerfield Beach</name>
      <address>
        <city>Deerfield Beach</city>
        <state>Florida</state>
        <zip>33442</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Miami Miller School of Medicine-Sylvester Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Kendall</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UM Sylvester Comprehensive Cancer Center at Plantation</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>305-243-2647</phone>
    </contact>
    <investigator>
      <last_name>Jose Lutzky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center-International Plaza</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Andrew S. Brohl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center - McKinley Campus</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Andrew S. Brohl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-679-0775</phone>
      <email>ClinicalTrials@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Andrew S. Brohl</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>312-695-1301</phone>
      <email>cancer@northwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Young Kwang Chae</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Clinical Research Center</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HaysMed University of Kansas Health System</name>
      <address>
        <city>Hays</city>
        <state>Kansas</state>
        <zip>67601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-623-5774</phone>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Olathe Health Cancer Center</name>
      <address>
        <city>Olathe</city>
        <state>Kansas</state>
        <zip>66061</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-355-8000</phone>
      <email>Jeni.wakefield@olathehealth.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ascension Via Christi - Pittsburg</name>
      <address>
        <city>Pittsburg</city>
        <state>Kansas</state>
        <zip>66762</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>620-235-7900</phone>
      <email>jennifer.jameson@ascension.org</email>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Salina Regional Health Center</name>
      <address>
        <city>Salina</city>
        <state>Kansas</state>
        <zip>67401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-452-7038</phone>
      <email>mleepers@srhc.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Health System Saint Francis Campus</name>
      <address>
        <city>Topeka</city>
        <state>Kansas</state>
        <zip>66606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>785-295-8000</phone>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Hospital-Westwood Cancer Center</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>913-588-3671</phone>
      <email>KUCC_Navigation@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kentucky/Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>859-257-3379</phone>
    </contact>
    <investigator>
      <last_name>John L. Villano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Institute Developmental Therapeutics Clinic</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-411-1222</phone>
    </contact>
    <investigator>
      <last_name>A P. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-411-1222</phone>
    </contact>
    <investigator>
      <last_name>A P. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-442-3324</phone>
    </contact>
    <investigator>
      <last_name>Geoffrey I. Shapiro</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Truman Medical Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64108</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>816-404-4375</phone>
    </contact>
    <investigator>
      <last_name>Benjamin C. Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Laura and Isaac Perlmutter Cancer Center at NYU Langone</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <email>CancerTrials@nyulangone.org</email>
    </contact>
    <investigator>
      <last_name>Vamsidhar Velcheti</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>212-305-6361</phone>
      <email>nr2616@cumc.columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Gary K. Schwartz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University at Clemmons</name>
      <address>
        <city>Clemmons</city>
        <state>North Carolina</state>
        <zip>27012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>888-716-9259</phone>
    </contact>
    <investigator>
      <last_name>Roy E. Strowd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>336-713-6771</phone>
    </contact>
    <investigator>
      <last_name>Roy E. Strowd</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Comprehensive Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>800-293-5066</phone>
      <email>Jamesline@osumc.edu</email>
    </contact>
    <investigator>
      <last_name>James L. Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute (UPCI)</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>412-647-8073</phone>
    </contact>
    <investigator>
      <last_name>Timothy F. Burns</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site Public Contact</last_name>
      <phone>877-632-6789</phone>
      <email>askmdanderson@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Vivek Subbiah</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 12, 2019</study_first_submitted>
  <study_first_submitted_qc>March 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2019</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page</ipd_description>
    <ipd_url>https://grants.nih.gov/policy/sharing.htm</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

